Efficacy of Gefitinib and Methorexate in Patients With Advanced Stage and Recurrent Head and Neck Cancer

Introduction: Gefitinib, a tyrosine kinase inhibitor (TKI), is an epidermal growth factor receptor (EGFR)-blocking drug that is effective in the treatment of lung cancer with EGFR mutations; however, its benefits for head and neck cancers are uncertain. Therefore, this study aims to determine the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Irshad, Razia, Haider, Ghulam, Hashmi, Madiha, Hassan, Anusha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260212/
https://www.ncbi.nlm.nih.gov/pubmed/34262802
http://dx.doi.org/10.7759/cureus.15451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260212/
https://www.ncbi.nlm.nih.gov/pubmed/34262802
http://dx.doi.org/10.7759/cureus.15451

Ejemplares similares